Pilot Study of 89-Zr Panitumumab in Pancreas Cancer
Reason given: Business Decision
Key facts
- Where
- Stanford, United StatesSee the site
- Phase
- Phase 1
Where in United States
- Stanford UniversityStanford, United StatesNo longer taking part
Trial details
- Who runs it
- Stanford University
- Trial code
- NCT04833959
- Record updated
- 21 June 2024
- Original description
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.Read full original descriptionShow less
Pilot Study of 89Zr Panitumumab in Pancreas Cancer
The main purpose of the study is to assess the safety of 89Zr-panitumumab as a molecular imaging agent in patients with (metastatic) pancreas cancer.
Inclusion: Confirmed diagnosis of pancreatic cancer.
Exclusion: Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment; Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents; History of infusion reactions to monoclonal antibody therapies; Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis; Severe renal disease or anuria; Known hypersensitivity to deferoxamine or any of its components; Pregnant or breastfeeding.